Immuntherapie beim metastasierten Mammakarzinom

Immune checkpoint inhibitors are playing an increasing role in the treatment of solid tumors. Currently, they are only approved for treatment of breast cancer in triple-negative tumors (estrogen, progesterone, and HER2 receptor negative). The following review therefore summarizes relevant agents, biomarkers, and data relevant to approval. In addition, immune-mediated side effects and a coarse overview of their treatment are presented.